Pesquisa da infecção oculta pelo vírus da hepatite B e avaliação da resposta vacinal em pacientes com diabetes mellitus tipo II em Goiânia-Goiás

Detalhes bibliográficos
Ano de defesa: 2016
Autor(a) principal: Pimentel, Kamilla Nogueira lattes
Orientador(a): Matos, Márcia Alves Dias de lattes
Banca de defesa: Matos, Márcia Alves Dias de lattes, Teles, Sheila Araújo, Fiacadori, Fabíola Souza
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Goiás
Programa de Pós-Graduação: Programa de Pós-graduação em Biologia da Relação Parasito-Hospedeiro (IPTSP)
Departamento: Instituto de Patologia Tropical e Saúde Pública - IPTSP (RG)
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tede/8024
Resumo: The hepatitis B virus infection (HBV) and diabetes mellitus type II represent serious public health problems and, the synergism between these two diseases, can affect the prognosis of the patients with increased risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma. The aims of the present study were to investigate the HBV occult infection and to evaluate the vaccine response in patients with diabetes mellitus type II, in Goiânia-Goiás. This study is part of the research "Investigation of the serological, epidemiological and molecular profile of the hepatitis B virus infection in patients with diabetes mellitus type 2 in Goiânia-Goiás" which was developed in five public health units Goiânia. After serologic screening of the population (n = 605), 108 anti-HBc positive patients/HBsAg negative were selected for the HBV-DNA research. For this, after extraction of viral genome, a semi-nested PCR was performed with primers complementary to region pre-S/S of HBV. Among the patients recruited in the units of the Family Health Program (N = 215) those susceptible to HBV infection (N = 172) were selected and invited to participate of the cohort about vacinal response. Thus, 128, 99 and 87 individuals agreed to receive the first, second, and third doses of recombinant vaccine Butang®, respectively. The subjects who received three doses of the vaccine and who agreed to participate in a new blood collection (N = 69) were evaluated for the quantitative detection of anti-HBs marker by enzyme-linked immunosorbent assay microparticle (MEIA) using the AxSYM system automation and AxSYM kits AUSAB (Brazil Abbot Laboratories). It was not found occult HBV infection in diabetic patients in Goiânia- Goiás, which is similar to that found in other population groups in Brazil. In relation to the vaccine response, of the 69 samples analyzed, was observed that 53.6% of patients were able to respond to vaccination, and the geometric mean of anti-HBs titres was 13.76 mIU/mL. The seroprotection rate found in diabetic patients in Goiânia- GO was considered low compared to the healthy adult population. Thus, the data obtained in this study may help in the planning of specific prevention actions of hepatitis B in a population that usually have comorbidities.